Swedish–British pharma giant focused on oncology, cardiovascular and more
A roundup of recent reports shows how debt, housing costs, and consumer spend patterns shape the US financial landscape. Redfin and Zillow data indicate ongoing affordability stress in housing, while consumer debt and money-management trends are highlighted by CNBC and independent outlets. The mix suggests a cautious, debt-aware economy.
Global markets have steadied as US retail data suggests consumer spending is softer while inflation trends remain in check. Traders are watching for Federal Reserve guidance as major indices hover near records after a week of mixed signals across equities, bonds and currencies.
Bloomberg reports a telehealth company has disclosed plans to sell already allowed compounds such as sermorelin and glutathione, which patients pursue for wellness benefits despite limited clinical evidence. The move underscores ongoing tensions between patient demand and scientific validation.
The FDA has approved daraxonrasib, sold as Rasonque by Revolution Medicines, for adults with previously treated or ineligible metastatic pancreatic cancer. Clinical trials have shown median survival extended to about 13.2 months versus roughly 6.7 months with chemotherapy. The drug will be available in the US with a roughly $39,800 monthly list price and expanded-access programmes have already treated thousands.
Arm Holdings chief executive Rene Haas says AI could one day help cure cancer, but the path is constrained by chip shortages and a demand surge for AI data centres. Multiple outlets report Haas’s remarks, framing a broaderAI-driven push in healthcare and manufacturing, while flagging supply constraints and broader market excitement.
The Guardian and The Scotsman analyze the evolving role of culture and arts funding in the UK. They highlight investments like Freelands’ £1.5m over five years to nurture art education and warn that cutting arts education infrastructure risks undermining community renewal and creative opportunity.
Three BBC investigations have revealed repeated failures in UK cancer care: a final review has found harm from misdiagnosis and inappropriate treatment by former Belfast neurologist Michael Watt; Coventry patients were prescribed temozolomide for years with little evidence of benefit; and England is missing cancer-treatment targets, with only 69.9% starting within 62 days. Officials and families are demanding answers.
Investors are recalibrating as AI executives urge caution on frontier development, sparking wide stock swings. A mix of weaker chip profits, higher oil prices and looming rate hikes are shaping a safer, slower AI era, while the potential IPOs and data-centre demand face renewed scrutiny.
Measles cases have surged nationwide with Pennsylvania reporting the highest tally this year. Health officials say vaccinations have risen, but distrust and political tensions are complicating containment. Fatalities from measles and related complications have occurred, including several unvaccinated individuals. The state faces hospitalizations and ongoing debates over public health responses.
Novo has laid out a plan to diversify beyond Wegovy and Ozempic as it faces looming exclusivity losses. Capital Markets Day signals a push into cardiovascular, liver and blood disorders with a target to expand its pipeline, while investors question credibility and near-term milestones amid a evolving GLP-1 landscape dominated by Lilly.
A wave of multi-million-dollar rounds in robotics and AI-enabled hardware signals a push to bring ‘physical AI’ into real-world production. Companies from Multiply Labs to FieldAI and SiMa.ai are racing to scale their robot-centric platforms, with strategic rounds aimed at forging scalable, cost-effective manufacturing and autonomous systems.
Late-stage trials show sacituzumab tirumotecan improves median overall survival to 19 months versus 12.1 months with chemotherapy, but with notable side effects. New ovarian cancer therapy rinatabart sesutecan also demonstrates a strong progression-free survival benefit. Other programs in the field report positive results, signaling a robust biotech landscape but with continued safety concerns.